Gd-nanoparticles functionalization with specific peptides for ß-amyloid plaques targeting by unknown




with specific peptides for ß-amyloid plaques 
targeting
Marie Plissonneau2,3†, Jonathan Pansieri1†, Laurence Heinrich‑Balard4,5, Jean‑François Morfin6, 
Nathalie Stransky‑Heilkron7, Pascaline Rivory4,5, Pierre Mowat1, Mireille Dumoulin8, Richard Cohen4,5,9, 
Éric Allémann7, Éva Tόth6, Maria Joao Saraiva10, Cédric Louis2, Olivier Tillement3, Vincent Forge1, François Lux3 
and Christel Marquette1* 
Abstract 
Background: Amyloidoses are characterized by the extracellular deposition of insoluble fibrillar proteinaceous 
aggregates highly organized into cross‑β structure and referred to as amyloid fibrils. Nowadays, the diagnosis of these 
diseases remains tedious and involves multiple examinations while an early and accurate protein typing is crucial for 
the patients’ treatment. Routinely used neuroimaging techniques such as magnetic resonance imaging (MRI) and 
positron emission tomography (PET) using Pittsburgh compound B, [11C]PIB, provide structural information and allow 
to assess the amyloid burden, respectively, but cannot discriminate between different amyloid deposits. Therefore, the 
availability of efficient multimodal imaging nanoparticles targeting specific amyloid fibrils would provide a minimally‑
invasive imaging tool useful for amyloidoses typing and early diagnosis. In the present study, we have functionalized 
gadolinium‑based MRI nanoparticles (AGuIX) with peptides highly specific for Aβ amyloid fibrils, LPFFD and KLVFF. 
The capacity of such nanoparticles grafted with peptide to discriminate among different amyloid proteins, was tested 
with Aβ(1–42) fibrils and with mutated‑(V30M) transthyretin (TTR) fibrils.
Results: The results of surface plasmon resonance studies showed that both functionalized nanoparticles interact 
with Aβ(1–42) fibrils with equilibrium dissociation constant (Kd) values of 403 and 350 µM respectively, whilst they 
did not interact with V30M‑TTR fibrils. Similar experiments, performed with PIB, displayed an interaction both with 
Aβ(1–42) fibrils and V30M‑TTR fibrils, with Kd values of 6 and 10 µM respectively, confirming this agent as a general 
amyloid fibril marker. Thereafter, the ability of functionalized nanoparticle to target and bind selectively Aβ aggregates 
was further investigated by immunohistochemistry on AD like‑neuropathology brain tissue. Pictures clearly indicated 
that KLVFF‑grafted or LPFFD‑grafted to AGuIX nanoparticle recognized and bound the Aβ amyloid plaque localized in 
the mouse hippocampus.
Conclusion: These results constitute a first step for considering these functionalized nanoparticles as a valuable 
multimodal imaging tool to selectively discriminate and diagnose amyloidoses.
Keywords: Beta‑amyloid fibrils, MRI contrast agent, Gadolinium based nanoparticles, Amyloid imaging, Peptide‑
targeting, Alzheimer’s disease
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Background
Amyloidoses constitute a wide range of human diseases 
which are related to the conversion of soluble proteins 
into well-organized and insoluble fibrillar deposits, due 
to protein misfolding and self-association into amyloid 
aggregates enriched with cross-β sheet structures [1] 
(Fig. 1a). There are approximately 40 disorders associated 
with amyloid fibril formation and deposition in the extra-
cellular space of various organs and tissues. They include 
neurodegenerative diseases (e.g. Alzheimer’s disease, 
AD), systemic amyloidoses (e.g. familial amyloid poly-
neuropathy, FAP) and localized amyloidoses (e.g. type 
II diabetes). Each disorder has a distinct clinical profile 
and is associated with the aggregation of a predominant 
peptide or protein [2], i.e. amyloid-β peptide (Aβ) in AD, 
transthyretin (TTR) in FAP, or amylin in type II diabe-
tes. Currently, the diagnosis of amyloidoses is established 
from the results of multiple invasive examinations [3, 4], 
and is complicated by the involvement of several organs, 
and by the fact that symptoms are unspecific. In recent 
years, amyloidoses attracted considerable interest from 
scientists in different disciplines, resulting in a better 
understanding of their pathogenesis and of the molecu-
lar mechanisms of amyloid formation. This knowledge 
has led to important advances useful for designing new 
tools to achieve early and reliable diagnosis of these 
pathologies.
Among amyloidosis, the major cause of dementia in the 
elderly population, Alzheimer’s disease is the most com-
mon age-related neurodegenerative disease. The number 
of people living with dementia worldwide is estimated at 
44 million, and is set to almost double by 2030 and more 
than triple by 2050 [5]. Establish AD diagnosis needs 
long and exhaustive cognitive test, completed by neuro-
imaging examination in order to be differentiated from 
other causes of dementia: vascular dementia, dementia 
with Lewis bodies, Parkinson’s disease with dementia, 
frontotemporal dementia and reversible dementias. The 
neuropathological hallmarks of AD include extracel-
lular plaques of Aβ peptide, intracellular neurofibrillary 
tangles and dystrophic neurites, which constitute the 
final markers attesting definitively of the disease. These 
histopathologic lesions are restricted to selective brain 
regions involved in memory and language, i.e. the hip-
pocampus and the cortex [6]. The progressive aggrega-
tion of Aβ peptides into plaque structures is one of the 
critical events leading to the progressive dismantling of 
synapses, neuronal circuits and networks [7–9], and to 
neurodegeneration [10, 11]. Interestingly, the appearance 
of amyloid plaques occurs years before the appearance of 
cognitive symptoms [12, 13] and is considered to be the 
distinct hallmark of early onset of the disease activat-
ing the sequential lesion events. Therefore, the in  vivo 
detection and quantification of amyloid species within 
the brain of patients at risk constitutes a promising strat-
egy for the early diagnosis and treatment of Alzheimer’s 
disease.
Currently, magnetic resonance imaging (MRI) is the 
preferred neuroimaging examination for AD as it allows 
an accurate measurement of brain structures’ volume, 
although a decrease of this latter appears to be a non-
specific and late feature of cerebral vascular diseases’ 
progression [14]. Thus, studies are under way to develop 
specific imaging markers for different types of dementia, 
including markers of senile plaques for very-high-field 
MRI and positron emission tomography (PET) [15]. A 
better characterization of the amyloid plaque presence 
and load in the brain can be also expected from imag-
ing approaches using amyloid ligands as imaging agents 
[16]. One of the most extensively used is the Pittsburgh 
compound B (PIB, [11C]2-(4′-methylaminophenyl)-6-
hydroxybenzothiazole), which binds with high affinity 
to any amyloid fibrils [17–21] and displays a PET signal 
in vivo, and correlates strongly with the amyloid burden 
[20]. Although several PET probes are currently under 
Fig. 1 a Schematic representation of self‑auto‑aggregation process 
leading to insoluble amyloid fibrils formation. b Strategy for specific 
amyloid protein targeting using AGuIX grafted with a selected 
peptide of Aβ. The nanoparticles are supposed to target the end of 
Aβ fibrils (represented in green) by the selected and grafted peptide, 
but not to amyloid fibrils of transthyretin (represented in yellow). c 
Transmission electronic microscopy pictures of Aβ amyloid fibrils after 
7 days of incubation and (d) of transthyretin amyloid fibrils formed 
with V30M mutated protein, at 20 days of incubation
Page 3 of 15Plissonneau et al. J Nanobiotechnol  (2016) 14:60 
clinical investigation, and preliminary results indicate 
that these tracers cannot differentiate between amyloid 
plaques at various stages and of different nature [17, 
19–23]. Indeed, irrespective of the neurodegenerative 
disease investigated, none of these studies have mapped 
Aβ pathologies in sufficient details to allow a quantita-
tive correlation between the PET signal and the amy-
loid burden in different regions of the brain. Thus, novel 
non-invasive Aβ binding substances suitable for in  vivo 
imaging, with high protein specificity and detection sen-
sitivity, need to be elaborated.
The development of multifunctional nanoparticles rep-
resents a breakthrough in medical imaging since these 
nanoobjects can meet the requirements of several imag-
ing techniques such as MRI, optical imaging or single 
photon emission CT (SPECT)/PET scintigraphy while 
offering excellent resolution and sensitivity. For instance, 
functionalization of such nanoparticles with specific 
biovectors allows their active targeting to tumors lead-
ing to a more accurate diagnosis [24]. Likewise, small Aβ 
peptides were coupled to gold nanoparticles in order to 
inhibit Aβ fibrillogenesis [25] or to ultrasmall superpara-
magnetic iron oxide nanoparticles in order to design con-
trast agents for Aβ plaque MRI imaging [26].
Recently, sub-5  nm gadolinium-based nanoparticles 
[27, 28] (AGuIX) have been developed that are suitable 
for multimodal detection: (1) in MRI, DOTAGa(Gd3+)-
grafted AGuIX nanoparticles led to significantly higher 
positive contrast when compared to classical molecular 
agents such as DOTAREM® [27, 29, 30]; (2) SPECT/PET 
can be carried out following radiolabeling; and (3) in vivo 
near infrared fluorescence imaging can be performed fol-
lowing the grafting of an appropriate fluorophore. Such 
multimodal imaging platform, gathering multi-detection 
possibilities, allows achieving, in vivo, a sensitive and reli-
able imaging. Furthermore, their functionalization with 
RGD peptides was realized in order to target and detect 
tumors [30, 31]. Due to their small size and biodegrada-
bility, AGuIX are efficiently eliminated from the body 
through renal clearance with no evidence of toxicity [32].
With the aim to develop a sensitive imaging tool which 
target amyloid fibrils and able to discriminate between 
different protein amyloid aggregates, we have focused 
on Aβ(1–42) fibrils as a proof of concept for amyloido-
sis. To this end, AGuIX nanoparticles were grafted with 
two small peptides derived from the sequence of Aβ(1–
42). The peptide KLVFF (corresponding to the hydro-
phobic core short Aβ(16–20) fragment) which is crucial 
for the formation of the β-sheet structures [33, 34] and 
binds to the full-length Aβ peptide via atypical antiparal-
lel β-sheet motif [35, 36], and the peptide LPFFD which 
binds to the central hydrophobic region of Aβ [37]. The 
rationale behind our investigation is that thanks to their 
capacity to co-aggregate with Aβ(1–42), KLVFF and 
LPFFD grafted on AGuIX are expected to target specifi-
cally the fibril ends of Aβ(1–42) deposits (Fig. 1b), their 
interaction is reported by fluorescence detection of a 
near infrared fluorophore (cyanine 5.5) also chemically 
grafted on AGuIX.
Results and discussion
In this work, we have optimized the functionalization 
of AGuIX nanoparticles with peptides in order to selec-
tively target Aβ(1–42) fibrils and detect amyloid plaque 
in AD animal tissue. AGuIX synthesis were firstly modi-
fied and optimized by addition of a PEG chain for LPFFD 
and KLVFF grafting optimization, the two selected 
Aβ(1–42) pentapeptides. Then, AGuIX@PEG@LPFFD 
and AGuIX@PEG@KLVFF were labeled with the near 
infrared fluorescent compound cyanine 5.5, allowing 
in  vitro and ex  vivo experiments. The binding specific-
ity was tested using amyloid fibril: (1) Aβ amyloid (1–42) 
fibrils, implicated into plaque amyloid burden in AD, and 
(2) Val->30->Met mutated transthyretin (V30M-TTR) 
fibrils [38, 39], one of the more than 80 identified muta-
tions on TTR as causative gene abnormality in FAP [40]. 
The efficiency of the selective interaction was also com-
pared with the PIB-binding to each amyloid fibril. Finally, 
the specificity of recognition of Aβ-grafted nanoparticles 
was achieved by immunohistochemistry experiments on 
brain sections of Alzheimer’s disease mouse model.
Nanoparticles functionalization with targeting peptides
AGuIX nanoparticles (Nps) were synthetized by an origi-
nal top–down process as previously described [29]. This 
synthesis led to the formation of Nps displaying a hydro-
dynamic diameter of 2.7 ± 0.7 nm and an average molec-
ular weight of 8.5 ± 1.0 kDa as judged by DLS and HPLC 
respectively (Additional file 1). The skeleton of the nano-
particles is composed of a polysiloxane network contain-
ing free amino functions obtained by the use of APTES 
((3-Amino)propyltriethoxy silane) precursor during sol/
gel process. The primary amine of APTES allows cova-
lent grafting of about ten DOTAGa (Gd3+) chelates per 
particle through amide bond formation resulting from 
the reaction of the amines with the anhydride function. 
Small chains of polyethylene glycol diacid (PEG) were 
added to nanoparticles with one end to be grafted cova-
lently to the nanoparticle, the other remaining available 
for peptide coupling (Additional file 1). The nanoparticles 
surface modification was monitored and characterized 
by complementary techniques, including Fourier Trans-
form Infrared spectroscopy (FTIR) and measurement of 
the ζ-potential (Additional file 1). Altogether, the results 
clearly indicated that PEG chains have been grafted to 
the nanoparticles, leading to about 5 carboxylic acid 
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functions per Np. Therefore, these AGuIX@PEG are suit-
able for peptides coupling (Additional file 1).
KLVFF and LPFFD were grafted to nanoparticles by 
amide formation thanks to classical carbodiimide chem-
istry between their N-terminal and the carboxylic acid 
function of the AGuIX@PEG (Additional file 1). Dynamic 
light scattering measurement (Fig.  2a) showed a slight 
increase of the Nps hydrodynamic diameter after peptide 
grafting: 3.2 ± 0.8 nm for the AGuIX@PEG@LPFFD and 
3.5 ± 0.9 nm for the AGuIX@PEG@KLVFF compared to 
2.9 ±  0.9  nm for the AGuIX@PEG. The shifts observed 
in relaxometry (Table  1), HPLC (Additional file  1), and 
DLS (Fig.  2a) are also in accordance with an efficient 
grafting of the peptides on AGuIX@PEG. The number of 
Aβ-peptides grafted to the nanoparticles was evaluated 
by far UV-circular dichroism at 1.6 ± 0.2 LPFFD-peptide 
per AGuIX@PEG and 2.25  ±  0.10 KLVFF-peptide per 
AGuIX@PEG (Fig.  2b). In parallel, elementary analyses 
were performed on the vectorized nanoparticles and con-
firmed the presence of about two peptides per nanoparti-
cle (Additional file 1). These findings were validated by the 
quantification of free amine in the nanoparticles using the 
trinitrobenzene sulfonic acid (TNBS) method [41] (Addi-
tional file 1).
The quality of both AGuIX@PEG@LPFFD and 
AGuIX@PEG@KLVFF as MRI contrast agent was veri-
fied according to their relaxivity values. Both longitu-
dinal (r1) and transversal (r2) relaxivities increased 
after peptide grafting. These high values are due to 
the important molecular weight of the Nps and to 
the rigidity induced by the Nps skeleton, leading to 
an increase of the rotation correlation time [42, 43]. 
Thus, the AGuIX@PEG showed a r1 = 12.0 s−1 mM−1 
and r2  =  18.7  s−1  mM−1, when these values rose 
for the AGuIX@PEG@LPFFD (r1  =  13.2  s−1  mM−1 
and r2  =  20.1  s−1  mM−1) and for the AGuIX@PEG@
KLVFF (r1 = 14.1 s−1.mM−1 and r2 = 23.0 s−1 mM−1). 
The r2/r1 ratios tend to one (Table  1). These values 
are significantly higher than those of the molecular 
contrast agents (DOTAREM®: r1 = 3.4 s−1 mM−1 and 
r2  =  4.8  s−1  mM−1 at 60  MHz) confirming the MRI 
positive contrast imaging feature of AGuIX nanoparti-
cles [44] (Table  1). These measures indicated that the 
two distinct nanoparticles grafted with specific Aβ 
Fig. 2 Amyloid peptide‑targeted AGuIX characterization: a hydrodynamic diameter measurements of AGuIX@PEG@KLVFF (pink) and AGuIX@PEG@
LPFFD (blue) by dynamic light scattering measurements (λ = 532 nm). b Quantification of the number of peptides grafted on AGuIX® nanoparticles. 
Circular dichroism signal of free KLVFF at 25, 50, 100, 200 mg L−1 at 212 nm (dotted lines) were reported on standard curve with reporting ellipcicity 
of peptide on nanoparticles in concentration function. To quantify the number of KLVFF grafted per nanoparticle, various dilution (from 50 to 150 
times) (continuous lines) were measure and reported on the graph with a number of peptide correspondence
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peptide have been obtained while maintaining appro-
priate MRI characteristics.
Cyanine 5.5 was chosen as dye-label for AGuIX@PEG@
LPFFD and AGuIX@PEG@KLVFF, to allow biophysics 
and ex vivo experiments due to absorption and emission 
wavelengths in the near infrared (λabs.max = 675 nm and 
λem.max =  695  nm). The grafting yield was estimated by 
comparing the Cy5.5 fluorescence intensity before and 
after purification and led to an amount of 1 dye for 170 
Np and 1 dye for 200 Np for AGuIX@PEG@LPFFD@
Cy5.5 and AGuIX@PEG@KLVFF@Cy5.5 respectively 
(Additional file 1).
In order to envisage these functionalized nanoparti-
cles as a safety contrast agent for a translation to in vivo, 
especially following the addition of small peptides which 
could introduce cytotoxicity changes of the nanoparti-
cles [45], innocuousness of functionalized nanoparticles 
has been assessed against neuronal cells. Cytotoxicity 
assays were performed using the viability test of MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) [46] on SH-SY5Y, and the results showed that 
AGuIX@PEG@LPFFD@Cy5.5, AGuIX@PEG@KLVFF@
Cy5.5 and AGuIX@PEG, do not exhibit any toxic effects 
on cells (Additional file 1). Indeed, more than 80 % of cells 
were alive after 1 h of incubation in the presence of nano-
particles corresponding to Gd3+ concentrations between 
0.5 and 2 mM in Gd3+. It is also interesting to note that 
even at higher concentration (5  mM Gd3+) more than 
75 % of cells were still alive. Previous biocompatibilities 
assays showed no adverse effects upon systemic AGuIX 
administration in healthy rodent [32] and those bearing 
melanoma, carcinoma [47] or gliosarcoma [48], and bio-
distribution studies indicated their renal excretion within 
few hours [32].
Aβ peptide grafted to AGuIX target specifically Aβ(1–42) 
fibrils
Formation of amyloid fibrils were obtained by incuba-
tion of Aβ(1–42) peptide and V30M-TTR protein under 
conditions favorable to aggregation in 3 and 10  days 
respectively. The final state of amyloid-fibril formation 
is controlled by transmission electron microscopy as 
illustrated on Fig. 1c and d: Aβ(1–42) fibrils are at least 
2 µm long with a wide of 10–15 nm (Fig. 1c), whereas the 
V30M-TTR amyloid fibrils form bundles of about several 
µm long and 20 nm wide (Fig. 1d).
In order to define an amyloid interaction “gold” stand-
ard, Kd values were evaluated using the PIB marker with 
Aβ(1–42) and V30M-TTR fibrils by partition experi-
ments. Following incubation of PIB with Aβ(1–42) or 
V30M-TTR fibrils, a first measure of the total fluores-
cence present in the mixture was realized as the total 
amount of PIB (Fig. 3a, dashed line). Then after centrifu-
gation of the mixture, the PIB fluorescence signal asso-
ciated to the pellet was measured (Fig.  3a double line), 
indicating thereof the PIB bound to the fibrils. Similar 
measure was performed with the supernatant allowing 
the evaluation of the unbound fluorescence (Fig. 3a, solid 
line). Experiments were performed with a range of con-
centrations of PIB (0.01–4 µM) and the results of fluores-
cent measurements associated with Aβ(1–42) (Fig.  3b) 
and V30M-TTR (Fig.  3c) fibrils were plotted. The fit of 
the experimental data with the Michaelis binding model 
(1:1) displayed Kd values equal to 6  µM for Aβ(1–42) 
fibrils (Fig. 3b) and 10 µM for V30M-TTR fibrils (Fig. 3c). 
These observations confirm that PIB binds different types 
of amyloid fibrils making it a general amyloid marker 
without protein discrimination (Fig.  3b, c). Similar 
experiments were then performed with AGuIX@PEG@
LPFFD@Cy5.5 and AGuIX@PEG@KLVFF@Cy5.5, on 
Aβ(1–42) fibrils, by measuring the related-Cy5.5 fluo-
rescence. For both nanoparticles, no fluorescence has 
been detected associated with fibrils (data not shown). 
Although partition method was adapted for the evalu-
ation of the interaction of PIB marker with fibrils, these 
latter results indicate that the amyloid fibrils interaction-
tests, with both functionalized nanoparticles, displayed 
certainly a lower detection sensitivity.
Therefore the ability of AGuIX@PEG@LPFFD@Cy5.5 
and of AGuIX@PEG@KLVFF@Cy5.5 to target amyloid 
fibrils was tested using surface plasmon resonance (SPR). 
This technique allows the observation of interaction in 
real-time on a sensor chip functionalized with 800 Res-
onance Unit (R.U.) of V30M-TTR fibrils or 1200 R.U. of 
Aβ(1–42) fibrils.
As KLVFF and LPFFD were described to interact with 
monomer forms of Aβ [37, 49], we ensured first that they 
interact with Aβ(1–42) fibrils. Then SPR experiments 
Table 1 Transversal and  longitudinal relaxivities of  the nanoparticles and  the molecular contrast agent DOTAREM®, 
and the ratio between their transversal and their longitudinal relaxivities at 60 MHz and 37 °C
AGuIX AGuIX@PEG AGuIX@PEG@LPFFD AGuIX@PEG@KLVFF DOTAREM®
r1 (s
−1 mM−1) 10 12 13.2 14.1 3.4
r2(s
−1 mM−1) 13.6 18.7 20.1 23.0 4.8
r2/r1 1.4 1.6 1.5 1.6 1.4
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were carried out with peptide alone, to determine their 
affinity onto Aβ(1–42) fibrils (Fig.  4a, b). These results 
indicate that both selected peptides recognize and inter-
act with Aβ(1–42) fibrils. The Kd calculated with the 
Biaevaluation® software were 393  ±  23  µM for KLVFF 
and 317 ± 48 µM for LPFFD.
Thereafter, to insure that the pegylation step of the 
Nps and the cyanine dye grafting did not induced unex-
pected binding, the number of R.U. remaining 141 s after 
the end of the nanoparticles injection was compared to 
those obtained with AGuIX@PEG, AGuIX@PEG@Cy5.5, 
AGuIX@PEG@LPFFD@Cy5.5 and AGuIX@PEG@
KLVFF@Cy5.5 at 2.5 mM in Gd3+ on Aβ(1–42) fibrils. As 
illustrated by histograms in Fig. 5a, while both AGuIX@
PEG@LPFFD@Cy5.5 and AGuIX@PEG@KLVFF@
Cy5.5 interact with Aβ(1–42) fibrils, AGuIX@PEG and 
AGuIX@PEG@Cy5.5 do not interact with amyloid fibrils.
Then, similar SPR experiments carried out with a range 
of nanoparticles concentrations (from 0.02 up to 6.4 mM 
expressed in peptide concentrations) showed that both 
AGuIX@PEG@LPFFD@Cy5.5 (Fig.  5b1) and AGuIX@
PEG@KLVFF@Cy5.5 (Fig.  5b2) interact with Aβ(1–42) 
fibrils. The sensorgrams obtained were fitted with the 
Biaevaluation® software (Langmuir 1:1). Each experiment 
was repeated three times and led to the dissociations con-
stants in the range of 534 ±  134 µM for AGuIX@PEG@
KLVFF@Cy5.5 and of 261  ±  59  µM for AGuIX@PEG@
LPFFD@Cy5.5. Although the Kd values are of several of 
hundred µM, these results demonstrate that the capacity 
of KLVFF and LPFFD to bind Aβ(1–42) fibrils is conserved 
after their grafting on AGuIX, with affinity of the same 
order of magnitude than those obtain with free peptides.
The specificity of these interactions for Aβ(1–42) fibrils 
was assessed in the same range of concentration of nano-
particles on a chip coated with V30M-TTR fibrils. As 
illustrated on Fig. 5c, 141 s after the end of nanoparticles 
injection, whereas both AGuIX@PEG@LPFFD@Cy5.5 
and AGuIX@PEG@KLVFF@Cy5.5 displayed an inter-
action on Aβ(1–42) fibrils (blue curves) dependent on 
nanoparticle concentrations injected, no specific inter-
action of any functionalized nanoparticles was recorded 
on V30M-TTR fibrils (red curves). This confirms the 
Fig. 3 Spectrofluometry measurement of PIB binding to Aβ (1–42) fibrils or V30M‑TTR fibrils following partition experiments (λex = 350 nm and 
λem = 420 nm). a 2 µM of PIB was added to 20 µM of amyloid fibrils (dotted line) and after 60 min., a pellet with fibrils and PIB bound (double lines) 
was separated from a supernatant with PIB alone (solid line). (b, c) Binding plots by fluorescence response at 420 nm of PIB bound on Aβ(1–42) 
fibrils (B) or V30M‑TTR fibrils (c) increasing concentration of PIB, fitted as Michaelis model (1:1)
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discriminatory feature of AGuIX@PEG@LPFFD@Cy5.5 
and AGuIX@PEG@KLVFF@Cy5.5 for Aβ(1-42) fibrils, 
supporting that the interactions between AGuIX@PEG@
LPFFD@Cy5.5 and AGuIX@PEG@KLVFF@Cy5.5 with 
Aβ(1-42) fibrils are indeed mediated by the targeting 
peptides KLVFF and LPFFD.
Altogether, these in  vitro experiments demonstrate 
that AGuIX nanoparticles functionalized with LPFFD or 
KLVFF, are able to bind and to discriminate Aβ(1–42) amy-
loid fibrils. Interestingly, it can be noticed that the grafting 
step of peptides on nanoparticles does not drastically mod-
ify the affinity of both peptide for the targeted fibrils.
Vectorized‑nanoparticles recognize Aβ plaques in AD mice 
brain
As next step, the ability of both AGuIX@PEG@LPFFD@
Cy5.5 and AGuIX@PEG@KLVFF@Cy5.5 to detect Aβ 
amyloid plaques into the brain of Alzheimer’s disease 
animal model was tested. For this purpose, immunohis-
tochemical experiments were performed on APPswe/
PS1A246E/TTR(−/−) transgenic mouse brain sections. 
Such 10  months old transgenic mice display amyloid 
plaques in the cortex and the hippocampus [50]. Simi-
lar experiments were performed on control animals of 
APPswe/PS1A246E/TTR(±), which do not contain amy-
loid deposits in the cortex and the hippocampus (Fig. 6b, 
d). AGuIX@PEG@LPFFD@Cy5.5 or AGuIX@PEG@
KLVFF@Cy5.5 was incubated on brain sections with or 
without amyloid deposits and visualized, owing to the 
grafted-Cy5.5 fluorescence by optic microscopy in the 
near infrared, while cellular nucleus were located using 
Hoechst dye.
As illustrated on Fig. 6, strong Cy5.5 fluorescence was 
visualized in AD brain sections, in specific structure 
(zoomed in a square Fig. 6a, c), with a core surrounded 
by diffuse fluorescence and by dots. These observations 
are characteristic of AD lesions constituted by amyloid 
plaque with cored and diffused deposits and dystrophic 
neurites in the vicinity of the plaque [51]. These struc-
tures are mainly constituted by Aβ(1–42) peptide into 
fibrillar β-sheet structure [52]. Similar experiments, on 
control brain sections without amyloid plaques, did not 
display such fluorescent staining as visualized in Fig. 6b 
and d.
The specificity of functionalized nanoparticles binding 
was verified, by incubating nanoparticles without grafted-
peptides, AGuIX@PEG@Cy5.5, on brain section contain-
ing amyloid burden. As expected, no amyloid plaque was 
stained by Cy5.5 fluorescence in hippocampus region 
(Fig. 6e). Although, some yellow dots were noticeable on 
the vessels and in the CA3 cell layer of the hippocampus 
and control immunostaining experiments with Cy5.5 
alone indicated this staining constitutes a background due 
to the Cy5.5 restricted to blood vessels (Additional file 1). 
Whereas, various other cyanine derivative dyes [53] can 
bind amyloid fibrils, the Cy5.5 molecule does not stain 
fibrils as observed in  vitro on fibrils (personal data) and 
on brain section of AD mouse model [54].
The selectivity of AGuIX@PEG@LPFFD@Cy5.5 and 
AGuIX@PEG@KLVFF@Cy5.5 for Aβ(1–42) amyloid 
deposits was also assessed using a nanoparticle grafted with 
a peptide non related to Aβ(1–42) fibrils, AGuIX@PEG@
TTR-peptide@Cy5.5. Immunohistochemistry performed 
on AD brain sections with this non related Aβ-peptide 
grafted nanoparticle, showed a low background related to 
cyanine5.5 fluorescence (Fig. 6f).
The Aβ burden of AD mouse model was evaluated 
using PIB for immunohistochemical staining as fluo-
rescent ligand on AD brain. Figure  6g resulted from 
the merge of both staining and revealed robust fluores-
cent dots with diffusing labeling localized in AD mouse 
Fig. 4 Interaction of KLVFF (a) and LPFFD (b) peptides at several con‑
centrations with Aβ(1–42) fibrils measured by SPR. The sensorgrams 
obtained (colored curves) were fitted thanks to the Biaevaluation® 
software with the Langmuir 1:1 model (black curves)
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Altogether, these results indicated that both AGuIX@
PEG@LPFFD@Cy5.5 and AGuIX@PEG@KLVFF@Cy5.5, 
bind selectively amyloid plaque constituted by Aβ protein 
on ex vivo AD mouse hippoacampus.
Conclusions
In this work, ultra-small gadolinium-nanoparticles were 
successfully grafted with two peptides targeting Aβ(1–
42) fibrils (KLVFF and LPFFD). Although these peptides 
are described as β-breakers due to their ability to inter-
act with Aβ monomer and to inhibit the formation of 
amyloid oligomers [56] and fibrils [36, 56, 57], they were 
shown to selectively interact with Aβ(1–42) amyloid 
fibrils as well. The binding affinity of the grafted peptide 
for Aβ(1–42) fibrils is in the range of the hundredth of 
µM, this remaining compatible with the injected dose 
usually used in clinical MRI applications and particularly 
for diagnosis. Histological examination of the nanopar-
ticles proved their ability to preferentially interact with 
amyloid plaques present in the brain of AD mouse model 
confirming their targeting potential. The selective inter-
action of the functionalized nanoparticles with Aβ(1–42) 
fibrils was confirmed by the lack of affinity for V30M-
TTR fibrils, amyloid fibrils implicated in FAP, another 
type of amyloidosis.
Characterization of these new nanoparticles confirms 
that they possess several of the features needed for bio-
medical neuroimaging: relaxivity’s measures showed that 
functionalized AGuIX conserve high positif MRI contrast 
allowing MRI signal enhancement, facilitating image 
interpretation [58]; the absence of AGuIX accumulation 
in certain organs [32], such as the liver or spleen, and 
their rapid renal elimination allow their consideration for 
in  vivo injection, as it’s well known that such phenom-
ena may constitute a limit to the use of certain contrast 
agents, as reported for iron oxide nanoparticles [59], 
where their long lasting presence can be associated with 
cellular cytotoxic effects [60, 61].
Besides the high MRI contrast of AGuIX, due to their 
enrichment in gadolinium chelates, these nanoparti-
cles can be formulated to create a multimodal imaging 
Fig. 5 Interaction of functionalized nanoparticles for Aβ(1–42) fibrils 
or V30M‑TTR fibrils assessed by SPR experiments. a Remaining signal 
of AGuIX@PEG, AGuIX@PEG@Cy5.5, AGuIX@PEG@LPFFD@Cy5.5 and 
AGuIX@PEG@KLVFF@Cy5.5 at 2.5 mM in Gd3+ on Aβ(1–42) fibrils. The 
R.U. were measured 141 s after the end of the analyte injection. b, c 
The sensorgrams (colored curves) obtained for AGuIX@PEG@LPFFD@
Cy5.5 (b) and for AGuIX@PEG@KLVFF@Cy5.5 (c) on Aβ(1–42) fibrils 
were fitted thanks to the Biaevaluation® software with the Langmuir 
1:1 model (black curves). c Remaining signal of AGuIX@PEG@LPFFD@
Cy5.5 (plain curves) and AGuIX@PEG@KLVFF@Cy5.5 (dashed curves) on 
Aβ(1–42) fibrils (blue) and V30M‑TTR fibrils (red). The R.U. values plotted 
on the graph correspond to the measures at the time‑point 141 s after 
the end of nanoparticles injection
◂
hippocampus (see in zoom square Fig. 6g). Such picture 
could be correlated with compact/cored amyloid plaque 
[55] and diffuse plaques [53].
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Fig. 6 LPFFD and KLVFF vectorized nanoparticles hybridization on brain slices of APPswe/PS1A246/TTR transgenic (a, c, e, f, g) and control (b, d, h) 
mice. Imaging beta‑amyloid plaques were visualized owing to Cy5.5 fluorescence grafted to AGuIX@PEG@LPFFD@Cy5.5 (zoom in a), and AGuIX@
PEG@KLVFF@Cy5.5 (zoom in c), in the near‑infra red (yellow color, λexc = 620 nm‑λem = 642 nm). Cellular nucleus of brain sections were located 
using Hoechst dye staining (blue color λexc = 350 nm‑λem = 405 nm). AGuIX@PEG@LPFFD@Cy5.5 and AGuIX@PEG@KLVFF@Cy5.5 binding specific‑
ity test were performed on brain section without amyloid plaques (b, d), and with nanoparticle without peptides, AGuIX@PEG@Cy5.5 (e), or with a 
non‑related Aβ(1‑42) peptide, AGuIX@PEG@TTR‑peptide@Cy5.5 (f) on brain section with amyloid plaques. Positive control of amyloid burden was 
performed using PIB staining on brain sections with (g) and without amyloid plaques (h). Ligands binding are detected by fluorescence imaging of 
PIB at 400 nm (blue color, g). Tissue architecture was highlighted by imaging actin‑phalloidin staining (g, h, red color, λexc = 540 nm‑λem = 570 nm)
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platform, and/or by coupling 68Ga derivatives for PET 
detection [62] and for instance by covalently grafting a 
near infrared fluorophore for small animal. In conclusion, 
the ability of targeting and typing amyloid fibrils, by these 
new multifunctional nanoparticles, constitutes a first step 
of a promise and powerful strategy for a reliable early 
detection and identification of amyloidoses. Their future 
development will constitute a diagnostic and theranostic 
tool for the monitoring of the disease progression and the 




hydrochloride (EDC,  >98.0  %), N-hydroxysuccin-
imide (NHS,  >97.0  %), gadolinium chloride hexa-
hydrate ([GdCl3·6H2O], 99  %), sodium hydroxide 
(NaOH, 99.99  %), hydrochloric acid (HCl, 36.5–38  %), 
sodium chloride (NaCl,  >99.5  %), dimethyl sulfoxide 
(DMSO,  >99.5  %), acetonitrile (CH3CN,  >99.9  %), tri-
fluoroacetic acid (TFA,  >99  %), trinitrobenzene sul-
fonic acid (TNBS) 1  M in water, sodium dodecyl 
sulfate (SDS,  >99  %), (3-aminopropyl)triethoxysilane 
(APTES,  >98  %), tetraethyl orthosilicate (TEOS;  >98  %) 
and Poly(ethylene glycol) bis(carboxymethyl) ether (PEG) 
with an average molecular weight Mn  =  250  g  mol−1 
were purchased from Aldrich Chemical (France) and 
used without further purification. Diethylene gly-
col (DEG, 99  %) was purchased from SDS Carlo Erba 
(France). Acetone (reagent grade) was purchased from 
Sodipro (France) and was used as received. Freeze-dried 
full peptides Aβ(1–42), small Aβ specific-peptide (LPFFD 
and KLVFF) (>98  %) and small TTR targeter peptide 
(>98  %) were purchased from Genecust (Luxembourg). 
Recombinant human V30M-TTR protein was obtained 
following cloning its gene in the plasmid pQE81L and 
its expression in Escherichia coli (M15). Briefly, bacte-
rial cultures were performed in LB medium, 100 µg mL−1 
ampicillin and 25  µg  mL−1 kanamycin, at 37  °C, under 
constant orbital shaking. Protein production was pur-
sued for 7 h after IPTG induction when the absorbance 
was 0.700 at 600  nm. The bacterial pellet of 50  mL of 
culture was resuspended in sodium phosphate 50  mM, 
pH 8, sodium chloride 300 mM, imidazole 10 mM, bet-
amercaptoethanol 10  mM, supplemented with 500  µL 
of a protease inhibitor, phenylmethylsulfonyl fluoride 
(Sigma, #78830), at 1 mM final and a cocktail of protease 
inhibitor EDTA-free (Roche, #11873580001). The sus-
pension was sonicated during a total time of 6 min with 
repeated cycles of 5/7  s off with an amplitude of 20  %, 
then centrifuged during 30 min at 100,000g, to pellet cel-
lular debris. The supernatant was filtered on 0.2 µm cut 
off filters. The purification of the protein was performed 
on immobilized metal ion chromatography (Chelating 
Fast Flow, Amersham #17057501), and dialyzed against 
20  mM·NH4HCO3 (membrane cutoff 1/10,000; 3500 
MWCO Spectrapore). Finally, the protein was freeze-
dried. The protein quality was checked by SDS PAGE gel 
15 %. The Pittsburgh compound-B (PIB) derivative mol-
ecule was synthetized according to the procedure already 
described in the literature [63]. Starting from the p-anisi-
dine, the p-nitrobenzoyl amide was readily obtained and 
then the corresponding thioamide was prepared by reac-
tion with Lawesson’s reagent. Finally, an oxidative cycli-
zation was done to lead to the benzothiazole derivative, 
and the nitro function was reduced to give compound 
(Synthesis’ details in Additional file 1).
Nanoparticles synthesis and functionalization
The AGuIX Nps were provided by Nano-H SAS (Saint-
Quentin Fallavier, France) and the DOTAGA anhydride 
(1,4,7,10-tetraazacyclododecane-1-glutaric anhydride-
4-7-10-triacetic acid) was purchased from CheMatech 
(Dijon, France). AGuIX syntheses were performed at 
room temperature. Nanoparticles concentrations are 
stated in mol  L−1 of Gd3+. AGuIX were synthetized as 
previously described [29] (see Additional file  1). These 
Nps are composed of a polysiloxane network which 
is surrounded by covalently grafted DOTAGa(Gd3+) 
chelate. During the first step, Poly(ethylene glycol) 
bis(carboxymethyl) ether (PEG) was grafted on AGuIX. 
The freeze-dried AGuIX nanoparticles were dispersed in 
water to reach a concentration of Gd3+ of 500  mM and 
then diluted ten times with a solution of diethylene glycol 
(DEG) at 80 °C. In parallel, the carboxylic acid functions 
of the PEG chains were activated with EDC and NHS cou-
pling reagents (EDC/NHS/PEG molar ratio 10:20:1). The 
NHS-ester formation was performed in anhydrous DMSO 
at 100 mM in PEG under stirring at room temperature for 
30 min. Then, the NHS-ester PEG solution was added to 
the nanoparticles suspension (PEG/Gd molar ratio 3:1) 
and the reaction mixture left for 12 h at room tempera-
ture. Finally, the Nps were diluted in ultrapure water in 
order to reach a volume percentage (%v) of DMSO below 
5  %. Purification of the nanoparticles was performed by 
tangential flow filtration on a 5  kDa molecular cutoff 
membrane. This step allows removing the unreacted rea-
gents and the degraded nanoparticles. The AGuIX@PEG 
nanoparticles were freeze-dried using a Christ Alpha 1–2 
lyophilizer until the covalent conjugation of the Aβ amy-
loid peptides. In a second time, freeze-dried AGuIX@
PEG nanoparticles were first dispersed in water to reach 
a concentration of Gd3+ of 500 mM, and then successively 
diluted ten times with DEG at 80 °C and then two times 
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with anhydrous DMSO, leading to final concentration of 
Gd3+ of 25 mM. The carboxylic functions of the NPs were 
activated by EDC and NHS (EDC/NHS/Gd molar ratio 
10:20:1) under stirring at room temperature for 30  min. 
The activated Nps suspension was divided into two ali-
quots: one to be grafted with each of the two Aβ spe-
cific peptides. Each peptide, dissolved at 100 mg mL−1 in 
anhydrous DMSO, was added to the Nps suspension and 
stirred for 12  h at room temperature. The nanoparticles 
were then diluted in ultrapure water in order to reach a 
concentration in DMSO below 5 %v and purified by tan-
gential filtration on a 5 kDa molecular cutoff membrane. 
This step allows removing the EDC/NHS activators, the 
unreacted peptides and the degraded nanoparticles. The 
suspension of purified AGuIX@PEG@Peptide nanopar-
ticles was set at 100 mM of Gd3+ in ultrapure water and 
the pH was adjusted to 7. Finally, AGuIX@PEG@Peptide 
Nps were grafted with the fluorophore, Cyanine 5.5 NHS, 
which was dissolved in anhydrous DMSO at 2.5 mg mL−1. 
This mixture was slowly added to the nanoparticles sus-
pension (Cy5.5/Gd molar ratio 1:1000). After 4 h of reac-
tion, the mixture was purified by tangential filtration with 
a Vivaspin® tube with a cutoff of 5 kDa in order to remove 
the ungrafted cyanine molecules, the NHS formed and 
the degraded particles. Finally the nanoparticles AGuIX@
PEG@Peptide@Cy5.5 were freeze-dried for storage using 
a Christ Alpha 1–2 lyophilizer. They are stable for months 
without alteration at room temperature.
Relaxivity measurements
Relaxivity measurements were performed on a Bruker® 
minispec mq60NMR analyzer (Brucker, USA) at 37  °C 
at 1.4 T (60 MHz). Samples were measured at a specific 
Gd3+ concentration (mM), calculated from ICP-OES. 
The longitudinal relaxation time T1 and the transverse 
relaxation time T2 (s) were measured at 60 MHz and at 
37 °C. Then the relaxivities ri (s−1 mM−1) were obtained 
according to the following formula:
where i = 1 or 2.
Dynamic light scattering (DLS)
Hydrodynamic diameters (DH) of the Nps were deter-
mined with a Zetasizer NanoS (laser He–Ne 532 nm) from 
Malvern Instrument® (5  mW, with 173° NIBS detector 
and narrow band filter). Attenuator was optimized by the 
device and position was set to the center of the cell. To per-
form the measurement, 1 mL of nanoparticles suspensions 
at 10 mM Gd3+ was poured in a 12 mm square polystyrene 
disposable cuvette after filtration on a 0.2 µm cut-off nylon 















High performance liquid chromatography (HPLC)
Gradient HPLC analysis was carried out using the Shi-
madzu® Prominence series UFLC system equipped with 
a CBM-20A controller bus module, an LC-20AD liquid 
chromatograph, a CTO-20A column oven, a SPD-20A 
UV–Visible detector allowing absorption measurement 
at two chosen wavelengths and a RF-20A fluorescence 
detector allowing fluorescence measurements at specific 
excitation and emission wavelengths. For all measure-
ments, the UV–visible detectors were set respectively at 
295 and 350 nm. Sample aliquots of 20 µL were injected in 
a 95 % solvent A—5 % solvent B (A = Milli-Q water/TFA 
99.9:0.1 v/v; B  =  CH3CN/Milli-Q water/TFA 90:9.9:0.1 
v/v/v) into a Jupiter C4 column (150 × 4.60 mm, 5 µm, 
300 Å, Phenomenex®) at a flow rate of 1 mL min−1 over 
5 min. In a second step, samples were eluted by a gradi-
ent from 5 to 90 % of solvent B in solvent A over 15 min. 
Finally, the concentration of solvent B was maintained 
over 5  min. Then, the concentration of solvent B was 
decreased to 5 % over a period of 5 min to re-equilibrate 
the system, followed by additional 5 min at this final con-
centration. Before each sample measurement, a baseline 
was recorded following the same conditions by loading 
Milli-Q water onto the injection loop.
Inductively coupled plasma‑optical emission spectroscopy 
(icp‑oes) analysis
Determination of the gadolinium content in a sample 
was performed by ICP-OES analysis with a Varian 710-
ES spectrometer. Before measuring Gd3+ concentration, 
samples of colloidal solution were dissolved in HNO3 
67  % at 80  °C for 2  h. The samples were then diluted 
10-fold in HNO3 5  %. Chemical analysis were also per-
formed on the as-prepared samples at the Service Central 
d’Analyses du CNRS (Villeurbanne, France) by ICP-MS 
and enabled determining the C, N, Si contents with a pre-
cision of 0.5 %.
Circular dichroism
Circular dichroism was used in order to determine 
the number of Aβ peptide grafted on the nanoparti-
cles. Standard curves of peptide KLVFF and LPFFD 
are obtained by successive dilutions in distilled water 
(300 µL), respectively at 25, 50, 100 200 mg L−1 and 20, 
50, 100, 200, 300 mg L−1. The freeze-dried nanoparticles 
were dissolved in distilled water at 5 mM, and diluted in 
300 µL of distilled water at 0.03, 0.05 and 0.1 mM. Spec-
tra of each sample were recorded in a 1 mm path length 
quartz cell on a JASCO J-815 CD spectrometer using 
a response time of 1  s, a scan speed of 200  nm  min−1 
and a bandwith of 4  nm. Thirty spectra were accumu-
lated and averaged in far UV (200–250 nm) at 20 °C and 
quantification was done at 212 nm (KLVFF) and 219 nm 
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(LPFFD). These wavelengths were selected on each pep-
tide spectrum as the more characteristic point obtained 
in function of their concentrations. The molar elliptic-
ity reported as a function of the peptide concentration 
and allowed determining the number of peptide per 
nanoparticles.
Beta‑amyloid fibrils growth
Freeze-dried Aβ(1–42) peptide (Genecust) was dis-
solved in distilled water at pH 11.0. The solution was fil-
trated through a spin 0.2 µm membrane filter (Millipore, 
#146560) to remove any aggregated species. The solution 
was stored at −20 °C. Aβ(1–42) fibrils were prepared by 
incubating monomer Aβ(1–42) peptide solution (final 
concentration at 100  μM) in Tyrode’s buffer (150  mM 
NaCl, 3 mM KCl, 10 mM HEPES pH 7.4, 10 mM glucose; 
pH 6.5) at 37 °C in 500 µL reaction volume on a rotating 
shaker (300 rpm) for 72 h. Fibril morphology formation 
was confirmed by TEM analysis (JEOL 1200EX).
V30M‑TTR amyloid fibrils growth
The protein V30M-TTR was directly dissolved in buffer 
A (KH2PO4 10 mM, KCl 100 mM, EDTA 1 mM, adjusted 
to pH  7 and filtrated with a spin 0.2  µm) and buffer 
B (C2H3NaO2 200  mM, KCl 100  mM, EDTA 1  mM, 
adjusted to pH 4.4, filtrated with a spin 0.2 µm), with the 
same volume of each buffer to obtain a final concentra-
tion at 32.3 µM of V30M-TTR protein (pH 4.6) in a 1 mL 
reaction volume. It was incubated on a rotating shaker 
(300 rpm) during 10 days at 70 °C. Fibril morphology for-
mation was confirmed by TEM analysis.
Transmission electronic microscopy
10  µL of Aβ(1–42) or V30M-TTR fibrils samples were 
adsorbed on to the clean face of a carbon film on mica 
sheet (carbon/mica interface) and negatively stained with 
1 % (w/v) uranyl acetate. Micrographs were recorded at 
80 kV using a JEOL 1200EX equipped with a Veleta cam-
era (Olympus) and iTEM software or at 200 kV on a FEI 
Tecnai™ G2 Sphera.
Binding assays
Twenty µM of Aβ(1–42) or V30M-TTR fibrils were incu-
bated with PIB at 0.01, 0.1, 0.4, 0.8, 1.2, 2 and 4  µM, or 
2  µM of AGuIX@PEG@KLVVF@Cy5.5 or AGuIX@
PEG@LPFFD@Cy5.5, saturated with 3  mM AGuIX, for 
60 min at room temperature in 500 µL of each prepared 
fibril buffer. A first measure of fluorescence was carried 
out on the mixture, which was then centrifuged for 25 min 
at 14000  rpm and 25  °C to obtain a pellet (containing 
fibrils) and a supernatant (containing free nanoparticles 
or PIB). The pellet was dispersed in 500 µL of fibril buffer. 
A second measure of fluorescence was realized both on 
the supernatant and the re-suspended pellet. Accord-
ing to the fluorescence properties of PIB (λexc = 350 nm, 
λem  =  420  nm) or cyanine 5.5 (λexc  =  600  nm, 
λem = 655 nm) spectrum of each sample was recorded in a 
1 cm path length quartz cell on a CD-spectrophotometer 
(JASCO J-815) using a response time of 1 s, a scan speed 
of 100 nm min−1, an excitation bandwith of 5 nm and an 
emission bandwith of 10 nm. Three spectra were accumu-
lated at 25  °C and averaged. Spectra are treated by sub-
tracting of the spectrum recorded for the buffer. Michaelis 
binding model was used to determine the dissociation 
constant (KD) following the equation: 
where Ym is the maximum of fluorescence (A.U).
Surface plasmon resonance assays
The surface plasmon resonance assays were performed 
using a BIAcore® 2000 biosensor. The instrument was 
equipped with a CM3 sensor chip (GE Healthcare®, 
Uppsala, Sweden). The interaction studies took place on 
a gold chip functionalized with carboxymethylated dex-
tran. The sensor surface itself form one wall of a flow cell, 
which is an integral part of the microfluidic system. All 
SPR experiments were performed at 25 °C. HEPES buffer 
(HBS-P, GE Healthcare®, 0.01  M HEPES, 0.15  M NaCl, 
0.005 % surfactant p20) was used as running buffer.
For immobilization, amine coupling reagents were 
obtained from the GE Healthcare® kit containing 0.2 M 
EDC in water, 0.05 M NHS in water and ethanolamine-
HCl pH 8.5. Prior immobilization, the size of the Aβ(1–
42) fibrils was reduced using an ultrasonic disruptor 
Sonoplus HD 2070 (Banderlin, Germany). The sonication 
was performed on ice at 40 W during 20 s (pulse of 0.6 s; 
interval of 0.4 s; mode PULS, cycle 6) [64]. Aβ(1–42) and 
V30M-TTR fibrils were immobilized on the flow cell 2 
and 4 respectively of a CM3 sensor chip with an amine 
coupling reaction. After the chip activation by EDC/NHS 
during 7 min, the fibrils were injected at: 10 µM in 10 mM 
sodium acetate pH 4 at a flow rate of 5 µL  min−1 dur-
ing 20 min for Aβ(1–42) fibrils or at 0.36 µM in 10 mM 
sodium acetate pH 5.5 at a flow rate of 5 µL min−1 during 
100 min for V30M-TTR fibrils. The immobilization levels 
were around 1200 respond units (R.U.) for the Aβ(1–42) 
fibrils and 800 R.U. for the V30M-TTR fibrils. The flow 
cell 1 and 3 from this chip were activated by EDC/NHS 
during 7 min and then deactivated by ethanolamine dur-
ing 7 min and used as reference surface.
Biacore® experiments gathered data from 3 cycles for 
each studied analyte. One cycle consisted in the injec-
tion of the compound to be tested for 3  min. A waiting 
period of 2.5 min under running buffer (HBS-P) followed 
this step. Then the surface was regenerated, using the GE 
y = Ym/(1+ (Kd/x)),
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Healthcare® regeneration scouting kit, to remove the ana-
lyte from the chip by injection of 2  M NaCl and 5  mM 
NaOH during 60 s. A stabilization period of 2 min under 
running buffer finished the cycle. For the kinetic assays, 
the nanoparticles were injected at the concentration of 
0.02; 0.2; 0.4; 0.8; 1.6; 3.2 and 6.4 mM in peptide (corre-
sponding to 0.1; 1; 2; 4; 8; 16 and 32 mM in Gd3+) in run-
ning buffer (HBS-P) with 10 % liquid dextran (non specific 
binding reducer, GE Healthcare®) to reduce unspecific 
interaction. The free peptides were injected at concentra-
tions ranging from 44 to 704 µM. Each experiment began 
with five cycles injecting running buffer instead of analyte 
to stabilize the baseline of the apparatus. On the other 
hand, channel 1 or 3 were maintained in their carboxy-
methylated dextran native form to serve as a reference 
and observe possible non-specific interactions. Results 
of the interaction between the analytes and the Aβ(1–42) 
or V30M-TTR fibrils were represented on a sensorgram 
expressed as respectively FC2-1 or FC4-3 (RU-RUdex-
tran) versus time. The data were processed by Biaevalua-
tion software (Biacore) and fitted using the 1:1 Langmuir 
binding model to obtain the equilibrium dissociation con-
stant (Kd). The step was performed for each of the three 
sets of experiments. The value of R.U. obtained 141 s after 
the end of the injection was compared for the AGuIX@
PEG, AGuIX@PEG@Cy5.5, AGuIX@PEG@LPFFD@
Cy5.5 and AGuIX@PEG@KLVFF@Cy5.5 at 2.5  mM in 
Gd3+ on Aβ(1–42) fibrils and V30M-TTR fibrils.
Animal models
APPswe/PS1A246E/TTR mouse model was generated 
in JM Saraiva’s lab by crossing APPswe/PS1A246E mice 
(B6/C3H background) with TTRnull mice (TTR  −/−) 
(SV129 background) [65]. These transgenic mice co-
express a chimeric mouse-human amyloid-protein pre-
cursor (APP) bearing a human A domain with mutations 
(K595N and M596L) linked to Swedish (Swe) familial AD 
(FAD) pedigrees and human presenilin 1 (PS1) bearing a 
mutation (A246E) which also causes FAD. Expression of 
both transgenes is under the control of the mouse prion 
protein promoter (PrP). Animals used in this work were 
female APP/PSEN/TTR(−/−) 10  months old, display-
ing a dramatic amyloid plaques burden. Six months old 
male APP/PSEN/TTR(±), displaying rare plaques and 
very low levels of detergent- and formic acid-soluble 
Aβ40 and Aβ42 proteins in the transgenic male brain 
[66] were used as control. Animals were housed in a con-
trolled environment (12-h light/dark cycle; temperature, 
22 ± 2 °C; humidity, 45–65 %), with food and water freely 
available. All procedures involving animals were car-
ried out in accordance with the European Communities 
Council Directive.
Immunohistochemistry and microscopy
Mice were deeply anesthetized with a mixture of keta-
mine and medetomidine. Brains were removed from the 
skull and bisected longitudinally: each half was fixed for 
24 h at 4  °C in 10 % neutral buffered formalin and then 
transferred to a 30  % sucrose solution for cryoprotec-
tion before cryostat sectioning (10 µm) for immunohis-
tochemical analyses. Sections were mounted on glass 
slides and allowed to dry at room temperature for a few 
minutes. They were washed three times in phosphate 
buffer saline (PBS), and incubated into permeabilization-
saturation buffer [PBS 1X, 0.3 % triton, 1 % bovine serum 
albumin] for 1 h at RT. Then incubation with, AGuIX@
PEG@KLVVF@Cy5.5, AGuIX@PEG@LPFFD@Cy5.5, 
AGuIX@Cy5.5 or AGuIX@PEG@TTR@Cy5.5 nanopar-
ticles at 3  nM of Cy5.5 (corresponding to 2  mM Gd3+) 
with, for non-specific saturation, 3 mM ungrafted nano-
particles, or PIB at 1 µM were incubated on section in the 
same buffer for 1h30 at RT. For amyloid burden control, 
sections were directly stained with Thioflavin-S (at 0.05 % 
in EtOH 50  %, Sigma, #T1892) according to standard 
practice. Cell staining was performed using the phalloi-
din-TRITC (Sigma, #P1951) in the case of slices treated 
with PIB. After the PBS wash, all the other sections were 
coverslipped with dabco-mowiol mounting medium with 
additional Hoechst to stain cell nucleus. Fluorescent 
images were observed using the proper filter for each 
marker: cyanine 5.5: λexcitation = 620 nm-λemission = 642 n
m, PIB or Hoechst: λexcitation = 350 nm-λemission = 405 n
m, phalloidin: λexcitation = 540 nm-λemission = 570 nm and 
Thioflavin-S: λexcitation = 450 nm-λemission = 488 nm using 
a Zeiss microscope Axiovert 200  M. Images were ana-
lyzed using Carl Zeiss AxioVision software.
Additional file
Additional file 1: Figure S1. Characterization of functionalized nanopar‑
ticles. Figure S2. Zeta potential versus pH of AGuIX (black) and AGuIX@
PEG (red). Figure S3. Reaction scheme for the synthesis of AGuIX@PEG@
Peptide@Cy5.5. Figure S4. Chromatograms obtained with at UV‑Visible 
absorption at λ =295 nm of the AGuIX@PEG, AGuIX@PEG@LPFFD and 
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